Radiation MucositisNCT06381635
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis
A study testing Manuka honey mixed with aloe vera gel in people with Radiation Mucositis, run by Ain Shams University at 2 sites in Egypt.
Trial summary
The goal of this [ type of study: Clinical trial] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients. The main question [s] ] is to [ learn about, test, compare etc.] it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Radiation Mucositis
- What is being tested?
- Manuka honey mixed with aloe vera gel
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 2 sitesEgypt
- Study dates
- 1 Apr 2024to 1 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- a) Patients with a confirmed histologic diagnosis of H\&N malignancy who are referred to non-palliative radiotherapy in the oral cavity.
- Patient who is receiving radiation therapy with IMRT or 3D techniques. c) Patients received 50-70 Gy of total radiation at the rate of 2 Gy/fraction daily and 5 fractions/week.
- Patient who received concurrent chemotherapy with radiotherapy e) Presence of Oral Mucositis f) Age 20-70 years old g) Willing to participate in the study. h) Able to complete the study assessments.
Who cannot join
- a) Have a confirmed or medically treated diabetes mellitus b) Radiotherapy within the last 6 months prior to this study c) Vulnerable patients
Trial locations and contacts
2 sites in 1 country.
Asma A. Abou Bakr, PHD contact
Egypt2 sites, 2 recruiting
- Recruiting
ain shams University
Cairo, 11565
hani wlliam, MD, +20 0001000093885, ethicscommittee.fdasurec@gmail.com
- Recruiting
Fatma E.Sayed
Cairo
Fatma E. Hassanein, PHD, +201000093885, fatmahassanein@dent.asu.edu.eg
Asma Abou Bakr, Asmaa.Aboubakr@bue.edu.eg
About this study
Official title: Synergistic Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis in Head and Neck Cancer Patients: Randomized Controlled Clinical Trial
The goal of this [ type of study: Clinical trial] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients.
The main question [s] ] is to [ learn about, test, compare etc.] it aims to answer are:
- Is Aloe Vera Gel and Manuka Honey effective in management of Radiation Induced Mucositis?
- Does Aloe Vera Gel and Manuka Honey affect the level of TGFβ1 and EGF in saliva of patients with radiation induced mucositis? participants will be asked to apply Aloe Vera Gel and Manuka Honey or saline three times daily during radiotherapy and 6 months after radiotherapy.
Read the detailed description
Head and neck cancer is the eighth common type among all cancer types all over the world [1] The treatment comprises surgery, radiotherapy, chemotherapy or a combination escorted by restoration therapy, and social support [2] Radiotherapy leads to irreversible loss of the reproductive integrity, the cell cycle necessary for cell growth, apoptosis, and necrosis of cancer cells [3] Conventional fraction size ranges from 1.8 to 3 Grays (Gy) per fraction over 4-6 weeks [4] The accumulative dose of radiation for the primary treatment of head and neck cancer treatment is 60-70 Gy, depending on the irradiation of the tumor [5].
Radiation affects malignant cells and is also absorbed by the oral mucosa and gastrointestinal mucosa, especially in rapidly dividing cells [6] Oral mucositis is the most frequent, distressing, painful, clinical side effect of radiotherapy [7] It is defined as an inflammatory lesion of oral mucosa resulting from the cancer therapy typically manifesting as atrophy, swelling, erythema, ulceration, and pseudomembrane formation [8,9] It is described in five overlapping stages: initiation, upregulation, message generation, ulceration, and healing [9,10].
Radiation-induced oral mucositis shows hyperkeratosis of the oral mucosa after the dose of 10-20 Gy [6,8] Erythema is the first clinical sign seen on the oral mucosa, and severity of mucositis reaches at a dose of 30 Gy. After the completion of radiotherapy, the symptoms abate in 2-6 weeks [11,12] Effective management of oral mucositis is very important [13,14].
Honey is an important traditional medicine and prophylactic agent that has numerous beneficial health properties including its ability to facilitate healing.[15,16] Honey helps in the reduction of ulceration and inflammation of the biological process of mucositis.[17,18] Honey has been used to manage burns, oral infections, surgical wounds, and pressure wounds.[19,20]. Honey was applied to the oral mucosa of patients undergoing radiotherapy which is beneficial in limiting the severity of oral mucositis. Honey is a natural product with rich nutritional properties that is economical and a pleasant agent for managing mucositis [21].
Manuka honey is a monofloral honey, produced from the nectar of flowers of Manuka tree. This variety is produced from the Apis mellifera honey bees, using New Zealand Manuka plants producing specific floral-variety named as Leptospermum scoparium [22]. Manuka honey is usually rated using a classification system known as the Unique Manuka Factor (UMF), which reflects the equivalent concentration of phenol (%, w/v) required to produce the same antibacterial activity as honey.
The composition of Manuka honey consists of carbohydrates, minerals, proteins, fatty acids, phenolic and flavonoid compounds. Although such compounds are found in other types of honey, other unique features also occur in Manuka honey, such as an unusually high level of methylglyoxal (MGO) formed from dihydroxyacetone (DHA) which correlates with antibacterial activity [23, 24]. Kato et al. also noted the occurrence of methyl syringate glycoside (leptosperin) as a unique maker for Manuka honey authentication [25]. Interestingly, the UMF rating of Manuka honey strongly correlates with MGO equivalence and antibacterial activity but the relation is not wholly understood [26]. In addition to antibacterial activity [22, 26], UMF honey has the ability to stimulate macrophages through Apalbumin 1 protein to release mediators such as TNF-α, IL-1β and IL-6, which are needed for reducing microbial infections and helping in tissue healing [27]. Manuka honey shows antioxidant and anticancer properties, which are considered due to its constituents-phytochemicals working as active bio-compounds [28, 29].
Aloe Vera (AV) is a cactus-like plant that grows readily in hot, dry climates. It belongs to the Liliacea family, of which there are about 360 species. Only two species are grown commercially: Aloe barbadensis Miller and Aloe aborescens. The parenchymatous cells in the fresh leaves of aloe vera secrete colorless mucilaginous gel (i.e., Aloe vera gel) that contains 98-99% water and 1-2% active compounds [30, 31] Aloe vera gel has various pharmacological actions like antibacterial, antifungal, anti-inflammatory, antioxidant, antitumour, hypoglycaemic properties and immune boosting. Therefore it is used traditionally as nutritional drinks, moisturizer, healing agent in cosmetics, diabetic patients, sun burn, wounds and digestive tract disorders, there is no adverse effect [32].
Aloe vera gel had also been used in dentistry and showed good results. It had been used for treatment of over extraction socket and endodontic medicament. Various dentifrices also contains Aloe vera gel as its constituent because of its medicinal property [33-34]. Studies have demonstrated that aloe vera has an important therapeutic uses in the management of oral lesions such as oral lichen planus, oral submucous fibrosis, radiation induced mucositis, burning mouth syndrome, xerostomia, recurrent apthous ulcers [31].
Transforming growth factor-β (TGF-β) is a family of related proteins that regulate many cellular processes including growth, differentiation, extracellular matrix formation and immunosuppression [35]. TGF-β protein is produced by nearly all normal cells and functions through a complex cell surface receptor system [36].
The three mammalian isoforms of TGF-β (TGF-βs 1, 2, and 3) have similar but distinct functions and are approximately 70% identical in amino acid sequence. Transforming growth factor-β (TGF-β) proteins and their antagonists have entered clinical trials. These multi-functional regulators of cell growth and differentiation induce extracellular matrix proteins and suppress the immune system making TGF-βs useful in treatment of wounds with impaired healing, mucositis, fractures, ischemia-reperfusion injuries, and autoimmune disease. In diseases such as keloids, glomerulonephritis and pulmonary fibrosis, excessive expression of TGF-β has been implicated as being responsible for accumulation of detrimental scar tissue. In these conditions, agents that block TGF-β have prevented or reversed disease. Similarly, in carcinogenesis, blocking TGF-β activity may be valuable in stimulating an immune response towards metastasis. As these blocking agents receive approval, we will likely have new therapies for previously recalcitrant diseases [37]. It has been stated that transforming growth factor-β3 (TGF-β3) negatively regulates epithelial cell proliferation and reduces the incidence of oral mucositis [38].
A great number of growth factors and cytokines are involved in the wound site [39]. Of the growth factors, basic fibroblast growth factor (bFGF), transforming growth factor (TGF-b), and platelet-derived growth factor (PDGF) are anti-inflammatory and the most important in the wound healing process [40]. The bFGF (FGF-2) is a member of the FGF's family and has been shown in several studies to be an essential growth factor for fibroblast and vascular endothelial cell [41]. bFGF is increased in acute wound healing and plays a role in granulation tissue formation, re-epithelization, and tissue remodeling [42]. Although clinical studies have shown that bFGF was not successful in the treatment of diabetic foot ulcers, topical bFGF application has been found to increase the healing of burns and venous ulcers [43, 44, 45]. Moreover, TGF-β and PDGF are both crucial for inflammation, granulation, angiogenesis, connective tissue regeneration, re-epithelization, and remodeling which stimulate macrophages by increasing the secretion of other growth factors [43, 46]. They stimulate collagen production, affect matrix formation, and inhibit metalloproteinase (MMP) activity, which degrades collagen deposition. Levels of PDGF, TGF-β, and FGF are decreased in chronic wounds.
Epidermal growth factor (EGF), first discovered in the submaxillary gland of a rat in 1962, comprises a single-chain polypeptide containing 53 amino acids [47, 48]. EGF was later discovered in various normal tissues and body fluids, including the skin, mucosa, tears, cornea, saliva, milk, semen, and fluids secreted by the duodenal glands [49, 50]. EGF helps maintain tissue homeostasis by regulating epithelial cell proliferation, growth, and migration. It also induces angiogenesis, which provides nutritional support for tissues. Thus, EGF plays an important role in wound healing and tissue generation and may be useful in the treatment of radiation-induced oral mucositis [51, 52].
- Conditions
- Radiation Mucositis
- Being tested
- Manuka honey mixed with aloe vera gel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Manuka honey mixed with aloe vera gelDietary supplement
a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
| Study group | Role | What they receive |
|---|---|---|
| intervention group | Experimental | patients will be given 20 mL of Manuka honey with aloe vera gel, 15 min before and after the radiotherapy. They were instructed to swallow slowly to smear the layer of honey on the oral and pharyngeal mucosa. Patients were also advised to take 20 mL of Manuka honey before sleeping in the night. This treatment protocol was followed from day 1 of radiation till 6 weeks. Receives: Dietary Supplement: Manuka honey mixed with aloe vera gel |
| Control group | Placebo comparator | patients will be given 20 mL of 0.9% of saline 15 min before and after radiotherapy [54]. They will be advised to rinse saline. They will be instructed to keep saline for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of saline in the same manner before sleeping. This treatment protocol was followed from day 1 of radiation till 6 weeks. Receives: Dietary Supplement: Manuka honey mixed with aloe vera gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis
World Health Organization Oral Toxicity Scale Grading of Oral Mucositis ranges from "1,2,3,4) the grade1 me
Measured: Three points: -"baseline which is at the starting of radiotherapy", -"the second of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline, while the end point is after six months of radiotherapy.
Secondary outcomes (2)
the level of salivary transforming growth factor beta 1
salivary level of transforming growth factor beta 1 assessment using enzyme linked immune assay may range from 10-4000ng/L
Measured: Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
the level of salivary Epidermal Growth factor (EGF)
salivary level of Epidermal Growth factor assessment using enzyme linked immune assay may range from 3.9-250 pg/mL
Measured: Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2024
- Study start1 Apr 2024
- Primary completion1 Oct 2024 (estimated)
- Study completion1 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Radiation MucositisStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Fatma E. Hassanein, PHD, Study director, lecturer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06381635
- Sponsor's protocol ID
- FD-BUE-REC: IRB000124920
- Status last verified
- Apr 2024
- First submitted
- 20 Apr 2024
- Last updated
- 24 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Synergistic Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis in Head and Neck Cancer Patients: Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT06381635
- Acronym / sponsor ID
- FD-BUE-REC: IRB000124920
- Conditions
- Radiation Mucositis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- 1 Oct 2024 (estimated)
- Study completion
- 1 Jan 2025 (estimated)
- First posted
- 24 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this [ type of study: Clinical trial] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients.
The main question [s] ] is to [ learn about, test, compare etc.] it aims to answer are:
- Is Aloe Vera Gel and Manuka Honey effective in management of Radiation Induced Mucositis?
- Does Aloe Vera Gel and Manuka Honey affect the level of TGFβ1 and EGF in saliva of patients with radiation induced mucositis? participants will be asked to apply Aloe Vera Gel and Manuka Honey or saline three times daily during radiotherapy and 6 months after radiotherapy.
Detailed description
Head and neck cancer is the eighth common type among all cancer types all over the world [1] The treatment comprises surgery, radiotherapy, chemotherapy or a combination escorted by restoration therapy, and social support [2] Radiotherapy leads to irreversible loss of the reproductive integrity, the cell cycle necessary for cell growth, apoptosis, and necrosis of cancer cells [3] Conventional fraction size ranges from 1.8 to 3 Grays (Gy) per fraction over 4-6 weeks [4] The accumulative dose of radiation for the primary treatment of head and neck cancer treatment is 60-70 Gy, depending on the irradiation of the tumor [5].
Radiation affects malignant cells and is also absorbed by the oral mucosa and gastrointestinal mucosa, especially in rapidly dividing cells [6] Oral mucositis is the most frequent, distressing, painful, clinical side effect of radiotherapy [7] It is defined as an inflammatory lesion of oral mucosa resulting from the cancer therapy typically manifesting as atrophy, swelling, erythema, ulceration, and pseudomembrane formation [8,9] It is described in five overlapping stages: initiation, upregulation, message generation, ulceration, and healing [9,10].
Radiation-induced oral mucositis shows hyperkeratosis of the oral mucosa after the dose of 10-20 Gy [6,8] Erythema is the first clinical sign seen on the oral mucosa, and severity of mucositis reaches at a dose of 30 Gy. After the completion of radiotherapy, the symptoms abate in 2-6 weeks [11,12] Effective management of oral mucositis is very important [13,14].
Honey is an important traditional medicine and prophylactic agent that has numerous beneficial health properties including its ability to facilitate healing.[15,16] Honey helps in the reduction of ulceration and inflammation of the biological process of mucositis.[17,18] Honey has been used to manage burns, oral infections, surgical wounds, and pressure wounds.[19,20]. Honey was applied to the oral mucosa of patients undergoing radiotherapy which is beneficial in limiting the severity of oral mucositis. Honey is a natural product with rich nutritional properties that is economical and a pleasant agent for managing mucositis [21].
Manuka honey is a monofloral honey, produced from the nectar of flowers of Manuka tree. This variety is produced from the Apis mellifera honey bees, using New Zealand Manuka plants producing specific floral-variety named as Leptospermum scoparium [22]. Manuka honey is usually rated using a classification system known as the Unique Manuka Factor (UMF), which reflects the equivalent concentration of phenol (%, w/v) required to produce the same antibacterial activity as honey.
The composition of Manuka honey consists of carbohydrates, minerals, proteins, fatty acids, phenolic and flavonoid compounds. Although such compounds are found in other types of honey, other unique features also occur in Manuka honey, such as an unusually high level of methylglyoxal (MGO) formed from dihydroxyacetone (DHA) which correlates with antibacterial activity [23, 24]. Kato et al. also noted the occurrence of methyl syringate glycoside (leptosperin) as a unique maker for Manuka honey authentication [25]. Interestingly, the UMF rating of Manuka honey strongly correlates with MGO equivalence and antibacterial activity but the relation is not wholly understood [26]. In addition to antibacterial activity [22, 26], UMF honey has the ability to stimulate macrophages through Apalbumin 1 protein to release mediators such as TNF-α, IL-1β and IL-6, which are needed for reducing microbial infections and helping in tissue healing [27]. Manuka honey shows antioxidant and anticancer properties, which are considered due to its constituents-phytochemicals working as active bio-compounds [28, 29].
Aloe Vera (AV) is a cactus-like plant that grows readily in hot, dry climates. It belongs to the Liliacea family, of which there are about 360 species. Only two species are grown commercially: Aloe barbadensis Miller and Aloe aborescens. The parenchymatous cells in the fresh leaves of aloe vera secrete colorless mucilaginous gel (i.e., Aloe vera gel) that contains 98-99% water and 1-2% active compounds [30, 31] Aloe vera gel has various pharmacological actions like antibacterial, antifungal, anti-inflammatory, antioxidant, antitumour, hypoglycaemic properties and immune boosting. Therefore it is used traditionally as nutritional drinks, moisturizer, healing agent in cosmetics, diabetic patients, sun burn, wounds and digestive tract disorders, there is no adverse effect [32].
Aloe vera gel had also been used in dentistry and showed good results. It had been used for treatment of over extraction socket and endodontic medicament. Various dentifrices also contains Aloe vera gel as its constituent because of its medicinal property [33-34]. Studies have demonstrated that aloe vera has an important therapeutic uses in the management of oral lesions such as oral lichen planus, oral submucous fibrosis, radiation induced mucositis, burning mouth syndrome, xerostomia, recurrent apthous ulcers [31].
Transforming growth factor-β (TGF-β) is a family of related proteins that regulate many cellular processes including growth, differentiation, extracellular matrix formation and immunosuppression [35]. TGF-β protein is produced by nearly all normal cells and functions through a complex cell surface receptor system [36].
The three mammalian isoforms of TGF-β (TGF-βs 1, 2, and 3) have similar but distinct functions and are approximately 70% identical in amino acid sequence. Transforming growth factor-β (TGF-β) proteins and their antagonists have entered clinical trials. These multi-functional regulators of cell growth and differentiation induce extracellular matrix proteins and suppress the immune system making TGF-βs useful in treatment of wounds with impaired healing, mucositis, fractures, ischemia-reperfusion injuries, and autoimmune disease. In diseases such as keloids, glomerulonephritis and pulmonary fibrosis, excessive expression of TGF-β has been implicated as being responsible for accumulation of detrimental scar tissue. In these conditions, agents that block TGF-β have prevented or reversed disease. Similarly, in carcinogenesis, blocking TGF-β activity may be valuable in stimulating an immune response towards metastasis. As these blocking agents receive approval, we will likely have new therapies for previously recalcitrant diseases [37]. It has been stated that transforming growth factor-β3 (TGF-β3) negatively regulates epithelial cell proliferation and reduces the incidence of oral mucositis [38].
A great number of growth factors and cytokines are involved in the wound site [39]. Of the growth factors, basic fibroblast growth factor (bFGF), transforming growth factor (TGF-b), and platelet-derived growth factor (PDGF) are anti-inflammatory and the most important in the wound healing process [40]. The bFGF (FGF-2) is a member of the FGF's family and has been shown in several studies to be an essential growth factor for fibroblast and vascular endothelial cell [41]. bFGF is increased in acute wound healing and plays a role in granulation tissue formation, re-epithelization, and tissue remodeling [42]. Although clinical studies have shown that bFGF was not successful in the treatment of diabetic foot ulcers, topical bFGF application has been found to increase the healing of burns and venous ulcers [43, 44, 45]. Moreover, TGF-β and PDGF are both crucial for inflammation, granulation, angiogenesis, connective tissue regeneration, re-epithelization, and remodeling which stimulate macrophages by increasing the secretion of other growth factors [43, 46]. They stimulate collagen production, affect matrix formation, and inhibit metalloproteinase (MMP) activity, which degrades collagen deposition. Levels of PDGF, TGF-β, and FGF are decreased in chronic wounds.
Epidermal growth factor (EGF), first discovered in the submaxillary gland of a rat in 1962, comprises a single-chain polypeptide containing 53 amino acids [47, 48]. EGF was later discovered in various normal tissues and body fluids, including the skin, mucosa, tears, cornea, saliva, milk, semen, and fluids secreted by the duodenal glands [49, 50]. EGF helps maintain tissue homeostasis by regulating epithelial cell proliferation, growth, and migration. It also induces angiogenesis, which provides nutritional support for tissues. Thus, EGF plays an important role in wound healing and tissue generation and may be useful in the treatment of radiation-induced oral mucositis [51, 52].
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intervention group | Experimental | Dietary Supplement: Manuka honey mixed with aloe vera gelpatients will be given 20 mL of Manuka honey with aloe vera gel, 15 min before and after the radiotherapy. They were instructed to swallow slowly to smear the layer of honey on the oral and pharyngeal mucosa. Patients were also advised to take 20 mL of Manuka honey before sleeping in the night. This treatment protocol was followed from day 1 of radiation till 6 weeks. |
| Control group | Placebo comparator | Dietary Supplement: Manuka honey mixed with aloe vera gelpatients will be given 20 mL of 0.9% of saline 15 min before and after radiotherapy [54]. They will be advised to rinse saline. They will be instructed to keep saline for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of saline in the same manner before sleeping. This treatment protocol was followed from day 1 of radiation till 6 weeks. |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- a) Patients with a confirmed histologic diagnosis of H\&N malignancy who are referred to non-palliative radiotherapy in the oral cavity.
Key exclusion criteria (1 listed)
- a) Have a confirmed or medically treated diabetes mellitus b) Radiotherapy within the last 6 months prior to this study c) Vulnerable patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Manuka honey mixed with aloe vera gela mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles. | Dietary supplement | Control group, intervention group |
Primary outcome
Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis
Time frame: Three points: -"baseline which is at the starting of radiotherapy", -"the second of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline, while the end point is after six months of radiotherapy.
World Health Organization Oral Toxicity Scale Grading of Oral Mucositis ranges from "1,2,3,4) the grade1 me
2 secondary outcomes
the level of salivary transforming growth factor beta 1
Time frame: Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
the level of salivary Epidermal Growth factor (EGF)
Time frame: Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2024.
- Individual participant dataSharing planned: No
Related trials for Radiation Mucositis
RecruitingPhase 2
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Radiotherapy-induced Oral Mucositis
RecruitingPhase 2
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Not yet recruiting
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Active, not recruiting
Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis
Mucositis Oral, Head and Neck Cancer
Not yet recruitingPhase 2
Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse
Head and Neck Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asma A. Abou Bakr, PHD contact
Fatma E. Hassanein, PHD study director
lecturer
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Manuka honey mixed with aloe vera gel in people with Radiation Mucositis, run by Ain Shams University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fatma E. Hassanein (+201000093885, fatmahassanein@dent.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis (time frame: Three points: -"baseline which is at the starting of radiotherapy", -"the second of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline, while the end point is after six months of radiotherapy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2024.